In Palmer v. Teva Canada Limited, the Ontario Court of Appeal upheld the lower court’s decision to deny certification of a proposed product liability class action seeking damages for the alleged increased risk of being...more
4/9/2024
/ Anticompetitive Behavior ,
Canada ,
Cancer ,
Cause of Action Accrual ,
Class Action ,
Class Certification ,
Damages ,
Healthcare ,
Life Sciences ,
Negligence ,
Ontario ,
Pharmaceutical Industry ,
Prescription Drugs ,
Product Recalls ,
Statutory Violations ,
Teva Pharmaceuticals ,
Unjust Enrichment